CRA provided expert testimony in litigation involving allegations that fraudulent reporting of list prices by pharmaceutical manufacturers affected reimbursement by insurers. CRA’s analyses addressed important features underlying pricing and reimbursement in the pharmaceutical industry, including the role of list prices and price reporting publications, the evolution of pricing mechanisms as a basis for reimbursement, and information held by various parties concerning pharmaceutical acquisition costs.
Rebalancing resources for healthcare and medicines: How much is enough?
This report identifies two key policy objectives that can be generated from healthcare and pharmaceutical spending.